Industry news

China is narrowing the U.S. lead in cancer research

Phil Taylor / Fierce Pharma

Chinese researchers are publishing more than three times as many research papers on cancer topics than they were a decade ago, closing the gap with their U.S. counterparts. China now has more than 17% of the global share of cancer research publications, up from around 5% in the mid-2000s, and now matches the output of the U.S. in 2005, according to a just-published report from science publisher Elsevier. 

07 December 2016

Clearside Biomedical, Inc. Announces Proposed Offering of Common Stock

Clearside Biomedical , Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has commenced an underwritten public offering of  $75 million  of shares of its common stock. All of the shares in the offering will be sold by Clearside. In addition, Clearside expects to grant the underwriters a 30-day option to purchase up to an additional  $11.25 million  of shares of common stock at the public offering price, less the underwriting discount.

U.S. patent agency to weigh rival claims on gene-editing technology

Brendan Pierson / Reute

The U.S. patent agency on Tuesday will hear arguments in a heated dispute over who was first to invent a revolutionary gene-editing technology known as CRISPR.

07 December 2016

Global medicine spending will reach nearly $1.5 trillion by 2021 on an invoice price basis - QuintilesIMS Institute

QuintilesIMS Institute

Global medicine spending will reach nearly $1.5 trillion by 2021 on an invoice price basis, up nearly $370 billion from the 2016 estimated spending level. Importantly for the outlook is that spending growth is slowing in 2016, declining from nearly 9% growth in 2014 and 2015 to just 4–7% CAGR over the next five years. 

Is the US biopharma industry headed for a turning point in 2017?

John Carroll / Endpoints News

Three months ago, Brent Saunders fired a shot across the bow of the USS Big Pharma, pledging to limit Allergan’s annual price increase on its portfolio drugs to no more than single-digit percentage hikes each year. On Monday, the new US president of diabetes specialist Novo Nordisk took that pledge. And 2017 is shaping up as a potential turning point in the heated public argument over drug prices in the US.

Small flu vax players poised to win 'sizable' share of market, firm predicts

Eric Sagonowsky / FiercePharma

As new flu vaccine technology emerges in the coming years, smaller players will have a shot at stealing market share from the world leaders who have for years had a hold on the market.

Pharma companies are upping their U.K. social media marketing game with country-specific accounts

Beth Snyder Bulik / FiercePharmaMarketing

Pharma social media guidelines in the U.S. are starkly different, and more open, than in other countries around the world. But that doesn’t mean pharma is simply sitting out social in other regions. In the U.K., for instance, more pharma companies are now adopting country-specific social media.

EU health regulator warns some hep C drugs could reactivate hep B

Vidya L Nathan, Muvija M, Natalie Grover / Reuters

The European Medicines Agency warned on Friday that some of the most successful hepatitis C treatments on the market could reactivate hepatitis B in patients, the second time this year it has raised safety concerns over these treatments.

Influenza vaccine ‘desperately’ needs improvement

Healio

The current seasonal influenza vaccine is not perfect, but experts agree that it remains the best available tool for fighting influenza — at least for now.

Pharma executives weigh in on possible changes under Trump

Ransdell Pierson, Bill Berkrot and Caroline Humer / Reuters

Top executives from large U.S. drugmakers on Thursday discussed for the first time possible changes for the industry under President-elect Donald Trump, and issues that have damaged the reputation of their industry.